Results 71 to 80 of about 196,988 (294)

Chaperone‐Mediated Autophagic Degradation of USP9X in Macrophages Exacerbates Postmyocardial Infarction Inflammation and Cardiac Dysfunction

Advanced Science, EarlyView.
This study demonstrates that inflammatory stimuli induce the acetylation‐triggered, chaperone‐mediated autophagic degradation of ubiquitin‐specific peptidase 9 X‐linked (USP9X) in macrophages. USP9X acts as a macrophage “inflammation switch” after myocardial infarction (MI). USP9X loss destabilizes tumor necrosis factor receptor‐associated factor (TRAF)
Biqing Wang, Xiangheng Cai, Mengqi Li, Xue Liu, Junhui Xue, Ye Liu, Ding Ai, Xinyang Hu   +7 more
wiley   +1 more source

Cell-based gene therapy for mending infarcted hearts [PDF]

, 2011
The goal of this study was to analyse the efficiency of a combinatorial cell/growth factor therapy to improve function of infarcted murine hearts. The Insulin-like Growth Factor-1 (IGF-1) isoform, IGF-1Ea, has been shown to reduce scar formation and ...
Poudel, Bhawana, Poudel, Bhawana
core   +1 more source

An analysis of electrocardiographic criteria for determining left ventricular hypertrophy

Arquivos Brasileiros de Cardiologia, 2002
OBJECTIVE: To determine the most sensitive criterion for the detection of left ventricular hypertrophy according to echocardiographically defined left ventricular mass.
Carlos Alberto Gasperin, Helio Germiniani, Carlos Roberto Facin, Admar Moraes de Souza, Cláudio Leinig Pereira da Cunha   +4 more
doaj   +1 more source

Decoding the Cardiac Immune Microenvironment and Fibroblast Crosstalk in Radiotherapy Combined with Immunotherapy‐Induced Cardiac Fibrosis Based on Single‐Cell Transcriptomic Analysis

Advanced Science, EarlyView.
This study highlights that radioimmunotherapy drives crosstalk between fibroblasts and immune cells (especially macrophages) in the cardiac microenvironment, with IL‐6 as the key mediator, and tocilizumab alleviates cardiac fibrosis by targeting this interplay.
Yuxi Luo, Ying Yu, Zhimin Zeng, Yanxin Chen, Yali Yi, Zhiqin Lu, Fujuan Zeng, Peng Xu, Daya Luo, Leifeng Chen, Anwen Liu   +10 more
wiley   +1 more source

Diagnostic value of R wave in aVL lead in left ventricular hypertrophy

Universidad Médica Pinareña, 2020
Introduction: left ventricular hypertrophy (LVH) is defined as the increase in the thickness of the wall or the interventricular septal portion (or both). This entity represents an important risk factor that is related to the increase in mortality.
Daniel Alejandro Denis-Piedra, Sheila Martínez-Gutiérrez, Albert Ramón Figueredo-Gilbert, Elia de la Caridad Rodríguez-Venegas   +3 more
doaj   +2 more sources

Asociación de la hipertrofía ventricular izquierda con eventos cardiacos posteriores a intervencionismo coronario percutáneo. Association of left ventricular hypertrophy with cardiac events after percutaneous coronary intervention. [PDF]

Revista Cubana de Cardiología y Cirugía Cardiovascular, 2011
Introduction: Left ventricular hypertrophy is not included in the prognostic models of cardiacevents after percutaneous coronary intervention.Objective To determine the association of left ventricular hypertrophy with the presenceof cardiac events during
Luis R. Llerena Rojas, María B. Cabalé Vilariño, Amaury Flores Sánchez   +2 more
doaj  

Rescue of Pressure Overload-Induced Heart Failure by Estrogen Therapy. [PDF]

, 2016
BackgroundEstrogen pretreatment has been shown to attenuate the development of heart hypertrophy, but it is not known whether estrogen could also rescue heart failure (HF).
Bopassa, Jean C, Centala, Alexander, Eghbali, Mansoureh, Iorga, Andrea, Li, Jingyuan, Nadadur, Rangarajan D, Ren, Shuxun, Saito, Tomoaki, Sharma, Salil, Stefani, Enrico, Toro, Ligia, Umar, Soban, Wang, Yibin   +12 more
core   +1 more source

A NeuroD1 AAV‐Based Gene Therapy for Functional Brain Repair in Alzheimer's Disease‐Like Non‐Human Primate Model

Advanced Science, EarlyView.
This study tests NeuroD1 AAV‐based gene therapy in a non‐human primate Alzheimer's disease model. The therapy prevents neuronal damage, inhibits hippocampal atrophy, and reduces neuroinflammation. It also repairs vascular and blood‐brain barrier damage, restores cerebrospinal fluid biomarkers, enhances hippocampal glucose metabolism, and improves ...
Zhouquan Jiang, Yongpeng Qin, Bin Luo, Fan Bai, Jiangyue Liu, Long Ma, Shu He, Rongjie Chen, Yuchen Wang, Shanggong Liu, Ying Sun, Yi Chen, Shuo Zhang, Jiaqi Liang, Feng Liao, Huiyi Wei, Junjie Wei, Lu Wang, Hao Xu, Zheng Wu, Gong Chen, Wenliang Lei   +21 more
wiley   +1 more source

A review of the molecular mechanisms underlying the development and progression of cardiac remodeling [PDF]

, 2017
Pathological molecular mechanisms involved in myocardial remodeling contribute to alter the existing structure of the heart, leading to cardiac dysfunction.
Angelini, Francesco, Bordin, Antonella, Carrizzo, Albino, Chimenti, Isotta, DE FALCO, Elena, Forte, Maurizio, Frati, Giacomo, Nocella, Cristina, Pagano, Francesca, Palmerio, Silvia, Schiavon, Sonia, Schirone, Leonardo, Sciarretta, Sebastiano, Valenti, Valentina, Vecchione, Carmine, Yee, Derek   +15 more
core   +3 more sources

TRIM40 Drives Pathological Cardiac Hypertrophy and Heart Failure via Ubiquitination of PKN2

Advanced Science, EarlyView.
This study identifies the E3 ligase TRIM40 as a key driver of pathological cardiac hypertrophy. TRIM40 binds PKN2 via its B‐box domain and, through its C29‐dependent catalytic activity, mediates K63‐linked ubiquitination of PKN2. This modification enhances PKN2 phosphorylation at Ser815, thereby driving hypertrophy.
Risheng Zhao, Xiaoli Cui, Huizhu Du, Zhuoqun Wang, Chang Liu, Linxin Zhang, Jianing Qi, Di Yang, Hui Yu, Shuang Yan, Wei Liu, Haiming Sun, Mengyang Wang   +12 more
wiley   +1 more source